GLP-1 RA: What GLP-1 Receptor Agonists Are

Complete guide: GLP-1 drugs: a complete guide to semaglutide and beyond

What GLP-1 RA means and what a GLP-1 receptor agonist is

GLP-1 RA (also written GLP-1RA) stands for GLP-1 receptor agonist: an agonist of the glucagon-like peptide-1 receptor. An agonist is a molecule that binds a receptor and switches it on the way the natural hormone does. Here the receptor is the one used by GLP-1, a hormone the gut releases when we eat; GLP-1 RAs are designed peptides that activate it and, unlike the hormone, resist its degradation¹².

The natural hormone stimulates insulin secretion in a glucose-dependent way², suppresses glucagon, slows gastric emptying and reduces appetite and food intake¹. In the first trials with exenatide and liraglutide, HbA1c fell by 1 to 2 percentage points and weight by 2 to 5 kg; the most common adverse event was mild nausea that lessened over time¹.

A note on vocabulary: tirzepatide also activates the GIP receptor and retatrutide adds glucagon, so they are described as dual or triple agonists rather than pure GLP-1 RAs. For the background on those molecules, read GLP-1 in plain words and the guide to semaglutide, tirzepatide and retatrutide.

Why the natural hormone does not work as a drug

GLP-1 has a pharmacological flaw: the enzyme dipeptidyl peptidase IV (DPP-4) cuts and inactivates it very quickly. In anesthetized pigs, the half-life of intact peptide was 1.0 minute; when DPP-IV was inhibited by more than 90%, it rose to 3.2 minutes and the effect on insulin was potentiated². A hormone destroyed within minutes cannot be given as a treatment.

Two strategies followed, laid out in a classic Lancet review¹: incretin mimetics (the GLP-1 RAs, resistant to degradation) and incretin enhancers (DPP-4 inhibitors such as sitagliptin and vildagliptin, which lower HbA1c by 0.5 to 1.0 points with few adverse events and no weight gain)¹. The key difference is that a DPP-4 inhibitor only prolongs the body's own hormone, while an agonist delivers a stronger pharmacological stimulus.

From lizard venom to semaglutide: how the class was engineered

In 1992, a group at the Bronx Veterans Affairs Medical Center isolated exendin-4, a 39-amino-acid peptide, from the venom of the Gila monster (Heloderma suspectum)³. Its synthetic version is exenatide, the first molecule of the class. Analogs of human GLP-1 came afterward, and the story of their design is essentially the story of lengthening the half-life: short-acting analogs first, then long-acting ones⁵.

Liraglutide is an acylated GLP-1 analog: a fatty acid attached to it lets it bind reversibly to serum albumin, which protects it and keeps it in circulation; it was approved for diabetes and, at 3.0 mg, for obesity⁴⁵. Semaglutide took the idea further. It has two amino-acid substitutions relative to human GLP-1 (Aib8 and Arg34) and is derivatized at lysine 26; the fatty acid and linker were chosen to maximize albumin affinity without losing receptor potency⁴.

A counterintuitive detail from the discovery paper: semaglutide's receptor affinity (0.38 nM) was three-fold lower than liraglutide's, yet its albumin affinity was higher, and its plasma half-life reached 46.1 hours in mini-pigs after intravenous administration⁴. In other words, the engineering goal was not a molecule that is more potent at the receptor, but one that persists long enough for weekly dosing. For the oral version, read oral semaglutide.

Short-acting and long-acting: how GLP-1 RAs are classified

The practical classification is by duration of action, which sets the dosing frequency and the drug's profile:

• Short-acting: exenatide given twice daily¹ and lixisenatide, whose cardiovascular trial was ELIXA¹¹. These are the first generation described in the history of the class⁵.
• Long-acting, once daily: liraglutide, with the LEADER trial and, at a higher dose, the SCALE obesity trial¹⁶¹⁵.
• Long-acting, once weekly: extended-release exenatide (EXSCEL), dulaglutide (REWIND), albiglutide (Harmony Outcomes) and semaglutide (SUSTAIN-6, SUSTAIN 7)^17891013.
• Oral formulation: oral semaglutide (PIONEER 6) was included in the class meta-analysis alongside the injectable forms¹².

What the cardiovascular outcome trials showed

A meta-analysis in The Lancet Diabetes & Endocrinology pooled seven trials with 56,004 participants with type 2 diabetes: ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND and PIONEER 6. The class reduced major adverse cardiovascular events (MACE) by 12% (HR 0.88; 95% CI 0.82–0.94), cardiovascular death (0.88), stroke (0.84), myocardial infarction (0.91), all-cause mortality (0.88), hospital admission for heart failure (0.91) and a broad kidney composite (0.83), mainly through lower urinary albumin excretion. There was no increase in severe hypoglycemia, pancreatitis or pancreatic cancer¹².

The individual results show why it is wrong to speak of a single class effect without nuance:

• LEADER (liraglutide): the primary outcome occurred in 13.0% versus 14.9% on placebo (HR 0.87); cardiovascular death was lower (HR 0.78)⁶.
• SUSTAIN-6 (semaglutide): 6.6% versus 8.9% (HR 0.74); nonfatal stroke was lower (HR 0.61)⁷.
• REWIND (dulaglutide): 12.0% versus 13.4% over a median of 5.4 years (HR 0.88); all-cause mortality did not differ significantly (HR 0.90; CI 0.80–1.01)⁸.
• Harmony Outcomes (albiglutide): HR 0.78 (CI 0.68–0.90), superior to placebo⁹.
• EXSCEL (once-weekly exenatide): HR 0.91 (CI 0.83–1.00); noninferior, but not superior (P=0.06)¹⁰.
• ELIXA (lixisenatide): 13.4% versus 13.2% (HR 1.02); noninferior, with no superiority¹¹.

Head-to-head comparisons: GLP-1 RAs are not interchangeable

Comparing separate trials is always indirect. Head-to-head trials are more informative. In SUSTAIN 7, an open-label phase 3b trial of 1,201 patients over 40 weeks, semaglutide lowered HbA1c by 1.5 points at 0.5 mg versus 1.1 with dulaglutide 0.75 mg, and by 1.8 at 1.0 mg versus 1.4 with dulaglutide 1.5 mg; weight fell by 4.6 kg versus 2.3 kg and by 6.5 kg versus 3.0 kg. Gastrointestinal events were the most frequent in both arms (33–48%)¹³.

In SURPASS-2, tirzepatide (5, 10 and 15 mg) was noninferior and superior to semaglutide 1 mg: HbA1c fell by 2.01, 2.24 and 2.30 points versus 1.86, and the weight difference was 1.9, 3.6 and 5.5 kg in favor of tirzepatide¹⁴. For the background on that molecule, see tirzepatide: the dual GIP/GLP-1 agonist.

In obesity without diabetes, the landmark trials are SCALE (liraglutide 3.0 mg: 8.4 kg versus 2.8 kg on placebo at 56 weeks; 63.2% lost at least 5% of body weight)¹⁵, STEP 1 (semaglutide: 14.9% mean weight loss)¹⁶ and SURMOUNT-1 (tirzepatide: up to 20.9% at the highest dose)¹⁷. These are different populations, durations and designs, so the figures cannot simply be subtracted from one another.

Safety: what repeats across the class

The most consistent pattern is gastrointestinal. In LEADER and SUSTAIN-6, the most common reasons for stopping treatment were gastrointestinal events⁶⁷. In REWIND, 47.4% of patients on dulaglutide reported a gastrointestinal event versus 34.1% on placebo (P<0.0001)⁸. Pancreatitis was numerically lower with liraglutide than with placebo in LEADER⁶, and the meta-analysis found no increase in pancreatitis, pancreatic cancer or severe hypoglycemia¹².

There are also signals that call for specific monitoring. In SUSTAIN-6 there were more retinopathy complications with semaglutide (HR 1.76; CI 1.11–2.78), a finding the authors reported alongside a lower rate of new or worsening nephropathy⁷. And a database study published in JAMA examined the association between GLP-1 RAs used for weight loss and gastrointestinal adverse events; because it is observational, it supplies a signal, not proof of causation¹⁸.